(2S)-4-benzylglutamic acid | 3283-43-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2S)-4-benzylglutamic acid
• 英文别名: γ-benzyl glutamic acid；γ-benzyl-L-glutamic acid；gammabenzyl glutamic acid；gamma-benzyl-L-glutamic acid；(2S)-2-amino-4-benzylpentanedioic acid
• CAS: 3283-43-0
• 化学式: C₁₂H₁₅NO₄
• 分子量: 237.255
• InChiKey: ATCFYQUZTYQTJN-AXDSSHIGSA-N

物化性质

• 熔点：
  174 °C
• 沸点：
  446.8±45.0 °C(Predicted)
• 密度：
  1.303±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  101
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (2S)-4-benzylglutamic acid 、 双(2,4-二硝基苯基)碳酸脂 以 四氢呋喃 为溶剂， 反应 84.0h， 以98%的产率得到N-carboxy-γ-benzyl-α-glutamic acid anhydride
  参考文献：
  名称：

  PROCESS FOR PRODUCING AMINO ACID N-CARBOXYANHYDRIDE

  摘要：

  本发明提供了一种制备氨基酸N-羧酸酐的方法，该方法包括使氨基酸或其衍生物与以下式(1)表示的化合物反应： 其中，R1和R2表示相同或不同的吸电子取代基，各自独立地为可任选取代的酰基、可任选取代的烷氧羰基、可任选取代的全氟烷基、可任选取代的全氯烷基、氰基、卤素原子或硝基；且a和b相同或不同，各自为1至5的整数。

  公开号：

  US20070015932A1
• 作为产物：
  描述：

  (rac)-4-benzyl-2-oxo-glutaric acid 在 bovine glutamic dehydrogenase 1,4-dihydronicotinamide adenine dinucleotide 、 L-谷氨酸 作用下， 以 phosphate buffer 为溶剂， 生成 (2S)-4-benzylglutamic acid
  参考文献：
  名称：

  Chemoenzymatic Synthesis of Glutamic Acid Analogues:  Substrate Specificity and Synthetic Applications of Branched Chain Aminotransferase from Escherichia coli

  摘要：

  [GRAPHICS]A new route to alpha-keto acids is described, based on the ozonolysis of enol acetates obtained from alpha-substituted beta-keto esters. Escherichia coli branched chain aminotransferase (BCAT) activity toward a variety of substituted 2-oxoglutaric acids was demonstrated analytically. BCAT was shown to have a broad substrate spectrum, complementary to that of aspartate aminotransferase, and to offer access to a variety of glutamic acid analogues. The usefulness of BCAT was demonstrated through the synthesis of several 3- and 4-substituted derivatives.

  DOI：

  10.1021/jo070805q

文献信息

• TROPAN COMPOUND
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1785421A1

  公开（公告）日：2007-05-16

  The conventional anticholinergic drugs for administration through inhalation have been considered to have the possibility of aggravating dysuria associated with prostatic hyperplasia mediated by blood, and it has been demanded that the conventional anticholinergic drugs for administration through inhalation will have to show reduced side effects or adverse ractions. The present invention relates to a compound represented by the general formula (I): (wherein A represents; and R1, R2, R3 and R1 each a hydrogen atom or a substituent; R5 is a substituent; X- is an anion;the symbol: denotes an exo-form or endo-form, or their mixture), its salt or solvation product thereof. They are useful as a prophylactic and/or therapeutic agent with reduced side effects or adverse reactions for the diseases mediated by the muscarinic receptor.

  传统的抗胆碱药物通过吸入给药被认为可能加重与前列腺增生相关的排尿困难，并要求传统的抗胆碱药物通过吸入给药必须显示减少副作用或不良反应。 本发明涉及一种由通式（I）表示的化合物： （其中A代表; 和R1、R2、R3和R1分别是氢原子或取代基; R5是取代基; X-是阴离子;符号: 表示外向型或内向型，或它们的混合物），其盐或溶剂化产物。它们可用作通过胆碱受体介导的疾病的预防和/或治疗剂，具有减少副作用或不良反应。
• [EN] ORGANIC COMPOUNDS<br/>[FR] COMPOSÉS ORGANIQUES
  申请人：INTRA CELLULAR THERAPIES INC

  公开号：WO2014145192A1

  公开（公告）日：2014-09-18

  The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D2 receptor signaling systems.

  该发明涉及特定的取代杂环融合的γ-咖啡碱，其前药，以自由的、药学上可接受的盐和/或基本纯净形式描述，以及其药物组合物，以及在治疗涉及5-HT2A受体、5-羟色胺转运体（SERT）和/或涉及多巴胺D2受体信号系统的疾病中的使用方法。
• [EN] NON-IONIC AND THERMORESPONSIVE DIBLOCK COPOLYPEPTIDE HYDROGELS FOR DELIVERY OF MOLECULES AND CELLS<br/>[FR] HYDROGELS DE COPOLYPEPTIDES DOUBLE BLOCS, NON-IONIQUES ET THERMOSENSIBLES, POUR L'ADMINISTRATION DE MOLÉCULES ET DE CELLULES
  申请人：UNIV CALIFORNIA

  公开号：WO2016054432A1

  公开（公告）日：2016-04-07

  The present invention is directed to copolypeptide hydrogels (DCH) containing non-ionic hydrophilic residues (DCHEO ), incorporation of thermoresponsive elements into DCHEO, to generate thermoresponsive DCH (DCHT), and hydrogels that include a combination of DCHEO and DCHT. The invention includes preparation, uses, compositions containing the hydrogels and methods of tuning the hydrogels. The hydrogels can be used to deliver an agent or cells to an organism.

  本发明涉及含有非离子亲水残基（DCHEO）的共聚肽水凝胶（DCH），将热响应元素并入DCHEO中，生成热响应DCH（DCHT），以及包括DCHEO和DCHT组合的水凝胶。该发明包括制备、用途、含有水凝胶的组合物以及调节水凝胶的方法。这些水凝胶可用于向生物体传递药剂或细胞。
• [EN] PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASAL INSULIN OF WHICH THE PI IS FROM 5.8 TO 8.5 AND A CO-POLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS AND A LIMITED AMOUNT OF M-CRESOL<br/>[FR] SOLUTION INJECTABLE DE PH 7 COMPRENANT AU MOINS UNE INSULINE BASALE À PI COMPRIS ENTRE 5,8 ET 8,5 ET UN ACIDE CO-POLYAMINO PORTANT DES CHARGES CARBOXYLATE ET DES RADICAUX HYDROPHOBES ET UNE QUANTITÉ LIMITÉE DE M-CRÉSOL
  申请人：ADOCIA

  公开号：WO2020115333A1

  公开（公告）日：2020-06-11

  The invention relates to physically stable compositions in the form of an injectable aqueous solution, the pH of which is from 6.0 to 8.0, comprising at least: a) a basal insulin whose isoelectric point (pI) is from 5.8 to 8.5, b) m-cresol in a concentration lower than or equal to 30 mM (0 < [m-cresol] ≤ 30 mM), and c) a co-polyamino acid bearing carboxylate charges and at least one Formula X hydrophobic radical.

  这项发明涉及一种物理稳定的组合物，其形式为可注射的水溶液，其pH值为6.0至8.0，包括至少：a) 一种碱性胰岛素，其等电点（pI）为5.8至8.5，b) 间甲酚的浓度低于或等于30毫摩尔（0 < [间甲酚] ≤ 30毫摩尔），以及c) 一种带有羧酸基团和至少一个X式疏水基团的共聚氨基酸。
• DIPEPTIDE MIMETICS OF NGF AND BDNF NEUROTROPHINS
  申请人：Seredenin Sergey Borisovich

  公开号：US20110312895A1

  公开（公告）日：2011-12-22

  The invention relates to compounds having either agonist or antagonist activities for the neurotrophins NGF and BDNF and represented by monomeric or dimeric substituted dipeptides that are analogs of the exposed portions of loop 1 or loop 4 regions of these neurotrophins near or at a beta-turn of the respective loop. N-acylated substituents of these dipeptides are biostereoisomers of the amino acid residues preceding these dipeptide sequences in the neurotrophin primary structure. The dimeric structure is produced advantageously by using hexamethylenediamine to which dipeptides are attached via their carboxyl groups. The claimed compounds displayed neuroprotective and differentiation-inducing activities in cellular models and enhanced the amount of phosphorylated tyrosine kinase A and the heat shock proteins Hsp32 and Hsp70 in the concentration range of 10 −9 to 10 −5 M. They also displayed neuroprotective, anti-parkinsonian, anti-stroke, anti-ischemic, anti-depressant and anti-amnestic activities in animal models and were active in experimental models of Alzheimer's disease. These in vivo effects of the claimed compounds are displayed in the dose range of 0.01 to 10 mg/kg when administered intraperitoneally.

  该发明涉及具有神经营养因子NGF和BDNF的激动剂或拮抗剂活性的化合物，这些化合物由单体或二聚体取代二肽代表，这些二肽代表这些神经营养因子的环1或环4区域的暴露部分的类似物，靠近或在各自环的β-转弯处。这些二肽的N-酰化取代物是神经营养因子原始结构中这些二肽序列之前的氨基酸残基的生物立体异构体。通过使用己二胺，优点地产生二聚体结构，二肽通过它们的羧基团连接到己二胺上。所述化合物在细胞模型中显示出神经保护和诱导分化活性，并在浓度范围为10^(-9)到10^(-5)M时增加了磷酸化酪氨酸激酶A和热休克蛋白Hsp32和Hsp70的量。它们还在动物模型中显示出神经保护、抗帕金森病、抗中风、抗缺血、抗抑郁和抗遗忘活性，并在阿尔茨海默病的实验模型中活跃。所述化合物的这些体内效应在腹腔内给药时的剂量范围为0.01至10毫克/千克。